A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown-CSU study.
antihistamine
chronic urticaria
cyclosporine
guideline
omalizumab
step down
urticaria control test
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
29
01
2024
received:
20
11
2023
accepted:
04
02
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
ppublish
Résumé
Although there have been significant advances in the treatment of chronic spontaneous urticaria (CSU) in recent years, there remains a lack of clear guidance on when and how to step down treatment in responders. This study aims to investigate stepping down approaches of different steps of CSU treatment from a global perspective. "Stepping down chronic spontaneous urticaria treatment" (SDown-CSU) is an international, multicenter, observational, cross-sectional, survey-based study of the Urticaria Centers of Reference and Excellence (UCARE) network. The questionnaire included 48 questions completed by physicians in the UCARE network. Surveys completed by 103 physicians from 81 UCAREs and 34 countries were analyzed. Seventy-eight percent of the participants responded that they had a national urticaria management guideline written by their professional societies and 28% responded that they had to operate under a regulatory guideline proposed by central health funding organizations. Seventy-two and 58.7% of these national recommendations do not contain any detailed information on when and/or how CSU treatment should be discontinued. There was a lack of detailed information on antihistamines and cyclosporine in particular. A predefined maximum duration was generally not applicable to omalizumab and cyclosporine (81% and 82%, respectively). Nearly all UCAREs step down omalizumab within 6 months from the first controlled status and 42% discontinue cyclosporine after 6 months regardless of the control status. The findings from the SDown-CSU study clearly highlight a global need for guidance on the process of stepping down treatment in CSU. Additionally, the study offers a step-down algorithm applicable to all stages of CSU treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Although there have been significant advances in the treatment of chronic spontaneous urticaria (CSU) in recent years, there remains a lack of clear guidance on when and how to step down treatment in responders. This study aims to investigate stepping down approaches of different steps of CSU treatment from a global perspective.
METHODS
METHODS
"Stepping down chronic spontaneous urticaria treatment" (SDown-CSU) is an international, multicenter, observational, cross-sectional, survey-based study of the Urticaria Centers of Reference and Excellence (UCARE) network. The questionnaire included 48 questions completed by physicians in the UCARE network.
RESULTS
RESULTS
Surveys completed by 103 physicians from 81 UCAREs and 34 countries were analyzed. Seventy-eight percent of the participants responded that they had a national urticaria management guideline written by their professional societies and 28% responded that they had to operate under a regulatory guideline proposed by central health funding organizations. Seventy-two and 58.7% of these national recommendations do not contain any detailed information on when and/or how CSU treatment should be discontinued. There was a lack of detailed information on antihistamines and cyclosporine in particular. A predefined maximum duration was generally not applicable to omalizumab and cyclosporine (81% and 82%, respectively). Nearly all UCAREs step down omalizumab within 6 months from the first controlled status and 42% discontinue cyclosporine after 6 months regardless of the control status.
CONCLUSIONS
CONCLUSIONS
The findings from the SDown-CSU study clearly highlight a global need for guidance on the process of stepping down treatment in CSU. Additionally, the study offers a step-down algorithm applicable to all stages of CSU treatment.
Types de publication
Journal Article
Langues
eng
Pagination
e12343Informations de copyright
© 2024 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Références
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of Urticaria. Allergy. 2022;77(3):734-766. https://doi.org/10.1111/all.15090
Fricke J, Ávila G, Keller T, et al. Prevalence of chronic Urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423-432. https://doi.org/10.1111/all.14037
Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous Urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-2016. https://doi.org/10.1111/all.13209
Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-1372. https://doi.org/10.1016/j.jaci.2013.12.1076
Cherrez-Ojeda I, Vanegas E, Cherrez A, et al. Chronic Urticaria patients are interested in apps to monitor their disease activity and control: a UCARE CURICT analysis. Clin Transl Allergy. 2021;11(10):e12089. https://doi.org/10.1002/clt2.12089
Neisinger S, Ramanauskaite A, Kocaturk E, et al. Embracing digital health solutions: the pivotal role of the CRUSE app in chronic spontaneous Urticaria management. Astım Allerji Immunoloji. 2023;21:1-3. https://doi.org/10.21911/aai.003
Saini SS, Kaplan AP. Chronic spontaneous Urticaria: the devil's itch. J Allergy Clin Immunol Pract. 2018;6(4):1097-1106. https://doi.org/10.1016/j.jaip.2018.04.013
Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, González-Aveledo L, Maurer M. Factors linked to disease severity and time to remission in patients with chronic spontaneous Urticaria. J Eur Acad Dermatol Venereol. 2017;31(6):964-971. https://doi.org/10.1111/jdv.14221
Türk M, Yılmaz İ, Şahiner ÜM, et al. Experience-based advice on stepping up and stepping down the therapeutic management of chronic spontaneous Urticaria: where is the guidance? Allergy. 2022;77(5):1626-1630. https://doi.org/10.1111/all.15227
Terhorst-Molawi D, Fox L, Siebenhaar F, Metz M, Maurer M. Stepping down treatment in chronic spontaneous Urticaria: what we know and what we don't know. Am J Clin Dermatol. 2023;24(3):397-404. https://doi.org/10.1007/s40257-023-00761-z
Kocaturk E, Saini SS, Rubeiz CJ, Bernstein JA. Existing and investigational medications for refractory chronic spontaneous Urticaria: safety, adverse effects, and monitoring. J Allergy Clin Immunol Pract. 2022;10(12):3099-3116. https://doi.org/10.1016/j.jaip.2022.09.038
Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Prim. 2022;8(1):61. https://doi.org/10.1038/s41572-022-00389-z
Maurer M, Metz M, Bindslev-Jensen C, et al. Definition, aims, and implementation of GA(2) LEN Urticaria centers of reference and excellence. Allergy. 2016;71(8):1210-1218. https://doi.org/10.1111/all.12901
Jia HX, He YL. Efficacy and safety of omalizumab for chronic spontaneous Urticaria: a systematic review and meta-analysis of randomized controlled trials. Am J Therapeut. 2020;27(5):e455. https://doi.org/10.1097/mjt.0000000000000912
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous Urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750. https://doi.org/10.1016/j.jaci.2015.12.1342
Lin WK, Lin SJ, Lee WR, et al. Effectiveness and safety of immunosuppressant’s and biological therapy for chronic spontaneous Urticaria: a network meta-analysis. Biomedicines. 2022;10(9):2152. https://doi.org/10.3390/biomedicines10092152
Ornek S, Kocaturk E. A patient-oriented approach to long-term use of omalizumab in chronic spontaneous Urticaria. Cutan Ocul Toxicol. 2021;40(4):305-311. https://doi.org/10.1080/15569527.2021.1945618
Giménez-Arnau AM, Jáuregui I, Silvestre-Salvador JF, et al. Consensus on the definition of control and remission in chronic Urticaria. J Investig Allergol Clin Immunol. 2022;32(4):261-269. https://doi.org/10.18176/jiaci.0820
Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous Urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113-124. https://doi.org/10.1016/j.jaip.2019.07.021
Giménez Arnau AM, Valero Santiago A, Bartra Tomás J, et al. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous Urticaria. J Investig Allergol Clin Immunol. 2019;29(5):338-348. https://doi.org/10.18176/jiaci.0323
Kolkhir P, Laires PA, Salameh P, et al. The benefit of complete response to treatment in patients with chronic spontaneous urticaria-CURE results. J Allergy Clin Immunol Pract. 2023;11(2):610-620. https://doi.org/10.1016/j.jaip.2022.11.016
Bernstein JA, Giménez-Arnau A, Maurer M, et al. Why a complete response is the treatment aim in chronic spontaneous Urticaria. J Clin Med. 2023;12(10):3561. https://doi.org/10.3390/jcm12103561
Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous Urticaria. J Allergy Clin Immunol. 2016;137(2):474-481. https://doi.org/10.1016/j.jaci.2015.08.023
Hew M, Gillman A, Sutherland M, et al. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin Exp Allergy. 2016;46(11):1407-1415. https://doi.org/10.1111/cea.12774
Ensina LF, Arruda LK, Campos RA, et al. H1-Antihistamines may no longer be necessary for patients with refractory chronic spontaneous Urticaria after initiation of omalizumab. J Investig Allergol Clin Immunol. 2020;30(2):145-147. https://doi.org/10.18176/jiaci.0464
Türk M, Yılmaz İ, Nazik Bahçecioğlu S, et al. Effectiveness of as-needed antihistamines in chronic spontaneous Urticaria patients under omalizumab treatment. Dermatol Ther. 2021;34(1):e14543. https://doi.org/10.1111/dth.14543
Türk M, Maurer M, Yılmaz İ. How to discontinue omalizumab in chronic spontaneous Urticaria? Allergy. 2019;74(4):821-824. https://doi.org/10.1111/all.13675